Medische Oncologie Nummer 3, pp. 27-31
okt 2006, jaargang 9
Medische Oncologie Nr. 3, pp. 27-31
okt 2006, jr. 9
Wetenschap

Weegt het voordeel op tegen de overgebleven dilemma’s? Adjuvante chemotherapie bij het niet-kleincellig longcarcinoom

In de afgelopen jaren zijn de resultaten van enkele grote studies met adjuvante chemotherapie na chirurgie bij vroege stadia niet-kleincellig longcarcinoom gepresenteerd. Een aantal studies liet een significant overlevingsvoordeel voor de adjuvante therapie zien. Er zijn echter ook een aantal studies met negatieve uitkomsten. Deze bevindingen plaatsen behandelaars in de dagelijkse praktijk voor een aantal dilemma’s.

Referenties

  1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-Small Cell Lung Cancer Collaborative Group.BMJ1995;311:899-909.
  2. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or III non-small cell lung cancer. Keller SM, Adak S, Wagner H, et al. N Engl J Med 2000;343:1217-22.
  3. Chemotherapy for patients with non-small cell lung cancer. The surgical setting of the BIG Lung Trial. Waller D, Peake MD, Stephens RJ, et al. Eur J Cargdiothorac Surg2004;26:173-82.
  4. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small cell lung cancer. Scagliotti GV, Fossati R, Torri V, et al. J Natl Cancer Inst2003;95:1453-61.
  5. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. International Adjuvant Lung Cancer Trial Collaborative Group.N Engl J Med 2004:350:351-60.
  6. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. Winton T, Livingston R, Johnson D, et al. N Engl J Med 2005;352: 2589-97.
  7. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of the Cancer and Leukemia Group B (CALGB) Protocol 9633. Strauss GM, Herndon J, Maddaus MA, et al. J Clin Oncol 2004;22 (suppl 14):S621.
  8. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small cell lung cancer (NSCLC) patients: final results after 70-month Med ian follow-up. On behalf of the Adjuvant Navelbine International Trialists Association. Douillard J, Rosell R, Delena M, et al. J Clin Oncol 2005;23(suppl 16):S624.
  9. Quality of life and preferences for treatment following systemic adjuvant therapy for early breast cancer. Lindley C, Vasa S, Sawyer WT, et al. J Clin Oncol 1998;16:1380-7.
  10. Patients’ preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwile? Jansen SJT, Kievit J, Nooij MA, et al. Br J Cancer 2001;84:1577-85.
  11. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. Strauss GM, Herndon JE, Maddaus MA, et al. J Clin Oncol 2006;24(suppl 18):S366.
  12. Guideline on non-small cell lung carcinoma: staging and treatment. Meerbeeck JP Van, Koning CCE, Tjan-Heijnen VCG, et al. Ned Tijdschr Geneeskd 2005;149:72-7.
  13. Lung adjuvant cisplatin evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. Pignon JP, Tribodet H, Scagliotti GV, et al. J Clin Oncol 2006;24(suppl 18):S366.
  14. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer: an Eastern Cooperative Oncol ogy Group (ECOG) Trial – E4599. Sandler A, Gray R, Brahmer J, et al. J Clin Oncol 2005:23(suppl 16):S2.
Wetenschap

Weegt het voordeel op tegen de overgebleven dilemma’s? Adjuvante chemotherapie bij het niet-kleincellig longcarcinoom

In de afgelopen jaren zijn de resultaten van enkele grote studies met adjuvante chemotherapie na chirurgie bij vroege stadia niet-kleincellig longcarcinoom gepresenteerd. Een aantal studies liet een significant overlevingsvoordeel voor de adjuvante therapie zien. Er zijn echter ook een aantal studies met negatieve uitkomsten. Deze bevindingen plaatsen behandelaars in de dagelijkse praktijk voor een aantal dilemma’s.

Referenties

  1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-Small Cell Lung Cancer Collaborative Group.BMJ1995;311:899-909.
  2. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or III non-small cell lung cancer. Keller SM, Adak S, Wagner H, et al. N Engl J Med 2000;343:1217-22.
  3. Chemotherapy for patients with non-small cell lung cancer. The surgical setting of the BIG Lung Trial. Waller D, Peake MD, Stephens RJ, et al. Eur J Cargdiothorac Surg2004;26:173-82.
  4. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small cell lung cancer. Scagliotti GV, Fossati R, Torri V, et al. J Natl Cancer Inst2003;95:1453-61.
  5. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. International Adjuvant Lung Cancer Trial Collaborative Group.N Engl J Med 2004:350:351-60.
  6. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. Winton T, Livingston R, Johnson D, et al. N Engl J Med 2005;352: 2589-97.
  7. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of the Cancer and Leukemia Group B (CALGB) Protocol 9633. Strauss GM, Herndon J, Maddaus MA, et al. J Clin Oncol 2004;22 (suppl 14):S621.
  8. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small cell lung cancer (NSCLC) patients: final results after 70-month Med ian follow-up. On behalf of the Adjuvant Navelbine International Trialists Association. Douillard J, Rosell R, Delena M, et al. J Clin Oncol 2005;23(suppl 16):S624.
  9. Quality of life and preferences for treatment following systemic adjuvant therapy for early breast cancer. Lindley C, Vasa S, Sawyer WT, et al. J Clin Oncol 1998;16:1380-7.
  10. Patients’ preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwile? Jansen SJT, Kievit J, Nooij MA, et al. Br J Cancer 2001;84:1577-85.
  11. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. Strauss GM, Herndon JE, Maddaus MA, et al. J Clin Oncol 2006;24(suppl 18):S366.
  12. Guideline on non-small cell lung carcinoma: staging and treatment. Meerbeeck JP Van, Koning CCE, Tjan-Heijnen VCG, et al. Ned Tijdschr Geneeskd 2005;149:72-7.
  13. Lung adjuvant cisplatin evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. Pignon JP, Tribodet H, Scagliotti GV, et al. J Clin Oncol 2006;24(suppl 18):S366.
  14. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer: an Eastern Cooperative Oncol ogy Group (ECOG) Trial – E4599. Sandler A, Gray R, Brahmer J, et al. J Clin Oncol 2005:23(suppl 16):S2.
Over dit artikel
Auteurs
Bonne Biesma, Vivianne Tjan-Heijnen
Over de auteurs

Bonne Biesma, longarts,
Vivianne Tjan-Heijnen, internist-oncoloog

Printdatum
14 oktober 2006
E-pubdatum
17 oktober 2006
ISSN print
1388-2295
ISSN online
2405-4763


Over dit artikel
Auteurs
Bonne Biesma, Vivianne Tjan-Heijnen
Over de auteurs

Bonne Biesma, longarts,
Vivianne Tjan-Heijnen, internist-oncoloog

Printdatum
14 oktober 2006
E-pubdatum
17 oktober 2006
ISSN print
1388-2295
ISSN online
2405-4763